Patients’ characteristics based on the diet assigned
| . | Total 222, n (%) . | Diet . | P value∗ . | |
|---|---|---|---|---|
| PD 111, n (%) . | NRD 111, n (%) . | |||
| Sex (female) | 96 (43) | 46 (41) | 50 (45) | .7 |
| Age, median (range) | 57 (22-72) | 57 (26-72) | 57 (22-71) | .1 |
| Disease | .7554 | |||
| Lymphomas | 105 (47) | 51 (46) | 54 (49) | |
| NHL aggressive | 65 (62) | 31 (61) | 34 (63) | |
| NHL indolent | 17 (16) | 10 (20) | 7 (13) | |
| HL | 23 (22) | 10 (20) | 13 (24) | |
| Multiple myeloma | 89 (40) | 48 (43) | 41 (37) | |
| AML | 9 (4) | 4 (4) | 5 (4) | |
| Other | 19 (9) | 8 (7) | 11 (10) | |
| Type of procedure | .9851 | |||
| Auto-HSCT | 175 (79) | 88 (79) | 87 (78) | |
| Allo-HSCT | 41 (18) | 20 (18) | 21 (19) | |
| High-dose CHT | 6 (3) | 3 (3) | 3 (3) | |
| Previous lines (≥2) | 106 (48) | 52 (47) | 54 (49) | .9 |
| Disease status at enrollment | .1233 | |||
| Complete response | 124 (56) | 66 (60) | 58 (52) | |
| Partial response | 74 (33) | 38 (34) | 36 (32) | |
| Stable disease | 10 (5) | 2 (2) | 8 (7) | |
| Progressive disease | 10 (5) | 3 (3) | 7 (7) | |
| Not applicable | 4 (2) | 2 (2) | 2 (2) | |
| Antimicrobial prophylaxis | ||||
| Antiviral | 219 (99) | 108 (97) | 111 (100) | .2 |
| Antibiotic† | 125 (56) | 61 (55) | 64 (57) | .7 |
| Antifungal | 212 (95) | 106 (95) | 106 (95) | > .99 |
| MDR colonization | 24 (11) | 12 (11) | 12 (11) | > .99 |
| Duration of neutropenia (days), median (range) | 6 (3-22) | 6 (3-20) | 6 (3-22) | .4 |
| . | Total 222, n (%) . | Diet . | P value∗ . | |
|---|---|---|---|---|
| PD 111, n (%) . | NRD 111, n (%) . | |||
| Sex (female) | 96 (43) | 46 (41) | 50 (45) | .7 |
| Age, median (range) | 57 (22-72) | 57 (26-72) | 57 (22-71) | .1 |
| Disease | .7554 | |||
| Lymphomas | 105 (47) | 51 (46) | 54 (49) | |
| NHL aggressive | 65 (62) | 31 (61) | 34 (63) | |
| NHL indolent | 17 (16) | 10 (20) | 7 (13) | |
| HL | 23 (22) | 10 (20) | 13 (24) | |
| Multiple myeloma | 89 (40) | 48 (43) | 41 (37) | |
| AML | 9 (4) | 4 (4) | 5 (4) | |
| Other | 19 (9) | 8 (7) | 11 (10) | |
| Type of procedure | .9851 | |||
| Auto-HSCT | 175 (79) | 88 (79) | 87 (78) | |
| Allo-HSCT | 41 (18) | 20 (18) | 21 (19) | |
| High-dose CHT | 6 (3) | 3 (3) | 3 (3) | |
| Previous lines (≥2) | 106 (48) | 52 (47) | 54 (49) | .9 |
| Disease status at enrollment | .1233 | |||
| Complete response | 124 (56) | 66 (60) | 58 (52) | |
| Partial response | 74 (33) | 38 (34) | 36 (32) | |
| Stable disease | 10 (5) | 2 (2) | 8 (7) | |
| Progressive disease | 10 (5) | 3 (3) | 7 (7) | |
| Not applicable | 4 (2) | 2 (2) | 2 (2) | |
| Antimicrobial prophylaxis | ||||
| Antiviral | 219 (99) | 108 (97) | 111 (100) | .2 |
| Antibiotic† | 125 (56) | 61 (55) | 64 (57) | .7 |
| Antifungal | 212 (95) | 106 (95) | 106 (95) | > .99 |
| MDR colonization | 24 (11) | 12 (11) | 12 (11) | > .99 |
| Duration of neutropenia (days), median (range) | 6 (3-22) | 6 (3-20) | 6 (3-22) | .4 |
AML, acute myeloid leukemia; high-dose CHT, high-dose chemotherapy with an expected period of neutropenia >7 days; NHL, non-Hodgkin lymphoma.
P value resulting from a Mann-Whitney test for continuous variables and χ2 test for categorical variables.
Among the 125 patients who received antibiotic prophylaxis, 119 (95%) received fluoroquinolones.